Hero image

Julie Louise Gerberding, M.D., M.P.H.

Chief patient officer and executive vice president, Population Health & Sustainability

As chief patient officer and executive vice president, Population Health & Sustainability, Dr. Julie Gerberding is responsible for patient engagement, corporate social responsibility, ESG and other functions. Formerly, Dr. Gerberding  oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as president of vaccines and was instrumental in increasing access to the company’s vaccines to people around the world.

Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through SARS and over 40 emergency responses to public health crises.  She serves on the Boards of Cerner Corporation and MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.  She also co-chairs the CSIS Commission on Strengthening America’s Health Security.

Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University and a Masters of Public Health at the University of California, Berkeley.  She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. 

Read Julie's latest insights

Lessons from dual pandemics

A conversation with Merck Chief Patient Officer Julie Gerberding, M.D., M.P.H., about her early work caring for people with HIV and AIDS, and the parallels of the AIDS and COVID-19 pandemics

Read more

Next: Lessons from dual pandemics

Antibiotic resistance: the hidden threat lurking behind COVID-19

Written by Julie L. Gerberding

Read more

Next: Antibiotic resistance: the hidden threat lurking behind COVID-19

Podcast: How Merck is looking at past epidemics and science to respond to the coronavirus outbreak

Listen as Merck’s Dr. Julie L. Gerberding, chief patient officer, and BIO’s Phyllis Arthur, VP, infectious diseases and diagnostics policy, discuss the outbreak and its public health impact Patrick Ryan, Merck director of communications, recently discussed the coronavirus outbreak with our own Dr. Julie L. Gerberding, executive vice president and chief patient officer, and Phyllis […]

Read more

Next: Podcast: How Merck is looking at past epidemics and science to respond to the coronavirus outbreak

Inside Davos 2020: the World Economic Forum

Global health challenges are getting more complex. Our company is working with leaders everywhere to solve them.

Read more

Next: Inside Davos 2020: the World Economic Forum

Lessons from dual pandemics

A conversation with Merck Chief Patient Officer Julie Gerberding, M.D., M.P.H., about her early work caring for people with HIV and AIDS, and the parallels of the AIDS and COVID-19 pandemics

Read more

Next: Lessons from dual pandemics

Antibiotic resistance: the hidden threat lurking behind COVID-19

Written by Julie L. Gerberding

Read more

Next: Antibiotic resistance: the hidden threat lurking behind COVID-19

Podcast: How Merck is looking at past epidemics and science to respond to the coronavirus outbreak

Listen as Merck’s Dr. Julie L. Gerberding, chief patient officer, and BIO’s Phyllis Arthur, VP, infectious diseases and diagnostics policy, discuss the outbreak and its public health impact Patrick Ryan, Merck director of communications, recently discussed the coronavirus outbreak with our own Dr. Julie L. Gerberding, executive vice president and chief patient officer, and Phyllis […]

Read more

Next: Podcast: How Merck is looking at past epidemics and science to respond to the coronavirus outbreak

Inside Davos 2020: the World Economic Forum

Global health challenges are getting more complex. Our company is working with leaders everywhere to solve them.

Read more

Next: Inside Davos 2020: the World Economic Forum

Previous
Next